Aripiprazole monohydrate
Based on 11 publication(s) in Google Scholar
Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.83%
- CAS 番号: 851220-85-4
- 分子式: C23H29Cl2N3O3
- 分子量:466.40
-
保管条件:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
MedChemExpress(MCE)の使用を引用している文献 Aripiprazole monohydrate
More- Nat Neurosci. 2022 Jan;25(1):39-49. [Abstract]
- Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279. [Abstract]
- CNS Neurosci Ther. 2024 May;30(5):e14739. [Abstract]
- Int J Pharm. 2020 Jun 15:583:119361. [Abstract]
- Int J Mol Sci. 2024 Jan 14;25(2):1035. [Abstract]
- ACS Omega. 2025 Oct 17;10(42):50208-50217. [Abstract]
- Mol Pharmacol. 2023 Nov;104(5):230-238. [Abstract]
- Fundam Clin Pharmacol. 2022 Dec;36(6):976-984. [Abstract]
- Korean J Physiol Pharmacol. 2020 Nov 1;24(6):545-553. [Abstract]
- University of South Carolina. 2025.
- Chemosphere. 2019 Jun:225:378-387. [Abstract]
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
5-HT Receptor アイソフォーム固有の製品をすべて表示
MoreDopamine Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
|
5-HT1A Receptor |
5-HT2A Receptor |
5-HT2B Receptor |
5-HT2C Receptor |
D2 Receptor |
D3 Receptor |
D4 Receptor |
Aripiprazole monohydrate potently activates D2 receptor-mediated inhibition of cAMP accumulation[1].
Aripiprazole monohydrate shows a greater anti-inflammatory effect on TNF-α, IL-13, IL-17α and fractalkine[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:WAG/Rij rats (N = 6 per dose, 6 months, administration of a mixture of tiletamine/zolazepam)[4]
-
Dosage:0, 0.3, 1, 3 mg/kg
-
Administration:IP, 1 mL/kg, every day at 5 p.m. until the end of the experiments
-
Result:Showed some anxiolytic properties with the 1 mg/kg dose being the most active.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 851220-85-4
-
性状 Solid
-
分子量 466.40
-
分子式 C23H29Cl2N3O3
-
Color White to off-white
-
SMILES
O=C1NC2=C(C=CC(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=C2)CC1.O
-
別名
OPC-14597 monohydrate
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Neurosci
Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties. [Abstract]2022 Jan;25(1):39-49. PMID: 34887590 -
Acta Pharmacol Sin
Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats. [Abstract]2021 Aug;42(8):1267-1279. PMID: 33976388 -
CNS Neurosci Ther
Correlation between desynchrony of hippocampal neural activity and hyperlocomotion in the model mice of schizophrenia and therapeutic effects of aripiprazole. [Abstract]2024 May;30(5):e14739. PMID: 38702935
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2024 May;30(5):e14739. [Abstract]
We evaluated the therapeutic effects of Aripiprazole (1 mg/kg, ip, single dose) on the electrophysiological activities of MK‐801‐treated mice.
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2024 May;30(5):e14739. [Abstract]
In the MK-801 group, theta power was significantly reduced by Aripiprazole (1 mg/kg, ip, single dose) treatment.
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2024 May;30(5):e14739. [Abstract]
The spontaneous spike activity of RS and FS units were significantly reduced by Aripiprazole (1 mg/kg, ip, single dose) treatment in the MK-801 group.
-
Int J Pharm
Enhanced dissolution, permeation and oral bioavailability of aripiprazole mixed micelles: In vitro and in vivo evaluation. [Abstract]2020 Jun 15:583:119361. PMID: 32334067 -
Int J Mol Sci
Differential Effects of Aripiprazole on Electroencephalography-Recorded Gamma-Band Auditory Steady-State Response, Spontaneous Gamma Oscillations and Behavior in a Schizophrenia Rat Model. [Abstract]2024 Jan 14;25(2):1035. PMID: 38256109
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Jan 14;25(2):1035. [Abstract]
Histogram showing the average percentage of change from the vehicle/vehicle-treated group for the PLF of the gamma-band ASSR recorded in rats' global cortex following an acute administration with Aripiprazole (0 and 3 mg/kg) and MK-801 in comparison with vehicle/vehicle-treated animals and MK-801/vehicle-treated animals.
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Jan 14;25(2):1035. [Abstract]
Horizontal activity plotted over 240 min following an acute administration with Aripiprazole (Ari) at 1, 3, 10 and 30 mg/kg in MK-801-treated rats in comparison with vehicle (Veh)/vehicle-treated, MK-801/vehicle-treated or MK-801/clozapine (Cloza)-treated rats (clozapine being used as a positive control).
-
ACS Omega
2025 Oct 17;10(42):50208-50217. PMID: 41179162 -
Mol Pharmacol
2023 Nov;104(5):230-238. PMID: 37567783 -
Fundam Clin Pharmacol
Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D2L receptor. [Abstract]2022 Dec;36(6):976-984. PMID: 35767599 -
Korean J Physiol Pharmacol
2020 Nov 1;24(6):545-553. PMID: 33093275 -
-
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Burris KD, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9. [Content Brief]
[2]. Davies MA, et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004 Winter;10(4):317-36. [Content Brief]
[3]. Crespo-Facorro B, et al. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Front Pharmacol. 2021 Mar 2;12:646701. [Content Brief]
[4]. Russo E, et al. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology. 2013 Jan;64:371-9. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)